Vialwirebiotech, curated
November 21, 2026, 9:14 AM
October 22, 2026
- 9:00 AM · BioWorld9:00 AMOrikine’s ORK-1 exerts disease control in IBD models — BioWorld
- 9:00 AM · BioWorld9:00 AMArbor Biotechnologies nominates gene editing candidates for ALS — BioWorld
- 9:00 AM · BioWorld9:00 AMOpus Genetics gains IND clearance for OPGx-RDH12 — BioWorld
- 9:00 AM · BioWorld9:00 AMMolecular Partners selects MP-0730 as radiotherapeutic candidate — BioWorld
- 9:00 AM · BioWorld9:00 AMRyvu’s RVU-602 shows potential as pan-cancer ADC payload — BioWorld
- 9:00 AM · BioWorld9:00 AMEANM 2026: Early data on CAIX-targeted radiopharmaceutical for ccRCC — BioWorld
- 8:33 AM · Pharmaceutical Technology8:33 AMAstraZeneca bags another US indication for Ultomiris with IgAN approval — Pharmaceutical Technology
- 5:39 AM · Drug Discovery World5:39 AMEnodia Therapeutics and Pfizer to develop Sec61-targeting small molecules — Drug Discovery World
- 5:31 AM · Pharmaceutical Technology5:31 AMAstellas and AI Proteins sign miniprotein therapeutics deal — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMSeed financing to address ‘liver trap’ in siRNA therapeutic delivery — Drug Discovery World
- 4:09 AM · Pharmaceutical Technology4:09 AMMSD’s Keytruda and Padcev combination receives EC approval — Pharmaceutical Technology
- 12:15 AM · Bloomberg — Technology12:15 AMVenture Capitalists Push Up AI Startup Valuations with Tranched, Two-Step Rounds — Bloomberg — Technology
- 12:00 AM · Nikkei Asia12:00 AMModerna CEO eyes China partnerships despite geopolitical tensions — Nikkei Asia
October 21, 2026
- 1:49 PM · STAT News1:49 PMSTAT+: What’s the deal with Isomorphic Labs? — STAT News
- 12:00 PM · BioWorld12:00 PMRoivant, Priovant targeting uveitis for next brepocitinib NDA — BioWorld
- 10:23 AM · BioPharma Dive10:23 AMArcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal — BioPharma Dive
- 10:17 AM · Pharmaceutical Technology10:17 AMFDA approves GSK’s Hibsago as first functional cure for hepatitis B — Pharmaceutical Technology
- 9:31 AM · Pharmaceutical Executive9:31 AM<![CDATA[CSL Names Deborah Waterhouse as CEO and Manager Director ]]> — Pharmaceutical Executive
- 9:23 AM · Drug Discovery World9:23 AMFirst clinical results from AKIR001 to be presented at EANM 2026 — Drug Discovery World
- 9:00 AM · BioWorld9:00 AMOrogen selects ORO-110, ORO-210 as development candidates — BioWorld
- 9:00 AM · PharmaVoice9:00 AMA CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech… — PharmaVoice
- 9:00 AM · BioWorld9:00 AMSaniona files IND for SAN-2465 for major depressive disorder — BioWorld
- 9:00 AM · BioWorld9:00 AMADC frenzy continues with $15B+ Roche-Hansoh deal — BioWorld
- 9:00 AM · BioWorld9:00 AMDARPA supports Rxmp Therapeutics’ hemorrhage treatment — BioWorld
- 9:00 AM · BioWorld9:00 AMAcrivon unveils CDK11 inhibitor ACR-7280 for acute myeloid leukemia — BioWorld
- 9:00 AM · BioWorld9:00 AMVisara signs option agreement for Yolo Immune’s YOL-104-2 — BioWorld
- 6:00 AM · Drug Discovery World6:00 AMIon channel blocker for autoimmune disease well tolerated in trial — Drug Discovery World
- 5:41 AM · Pharmaceutical Technology5:41 AMFDA approves Cosette’s Evoxac oral solution for Sjögren’s disease — Pharmaceutical Technology
- 5:08 AM · Pharmaceutical Technology5:08 AMMHRA revokes approval for Valneva’s Ixchiq due to safety frailties — Pharmaceutical Technology
- 4:37 AM · Pharmaceutical Technology4:37 AMSanofi and ScionxBio partner on mRNA therapies — Pharmaceutical Technology
- 4:30 AM · STAT News4:30 AMSTAT+: Mark Cuban wants to crack open the market for rare disease treatments — STAT News
- 4:30 AM · STAT News
- 12:05 AM · Science (News)
October 20, 2026
- 4:35 PM · TechCrunch4:35 PMOpenAI acquires startup Orchestra Bio to beef up its biotech business — TechCrunch
- 12:47 PM · STAT News12:47 PMSTAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole — STAT News
- 12:27 PM · BioPharma Dive12:27 PMRapport’s epilepsy drug finds surprising success in bipolar trial — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMZydus, Formycon move to front of Keytruda biosimilar race — BioWorld
- 12:00 PM · BioWorld12:00 PMTakeda cuts infusion burden with 20% Ig in pivotal PID study — BioWorld
- 12:00 PM · BioWorld12:00 PMAbbvie, Vertex lead $32B September biopharma M&A surge — BioWorld
- 12:00 PM · BioWorld12:00 PMFinancings: First Tracks, Recursion add $200M in private placements — BioWorld
- 12:00 PM · BioWorld12:00 PMIndia caps supply chain margins at 30% for 137 cancer drugs — BioWorld
- 12:00 PM · BioWorld12:00 PM‘Meme stock phenomenon’ at play in Cassava class action — BioWorld
- 12:00 PM · BioWorld12:00 PMLabcorp acquisition spree continues — BioWorld
- 12:00 PM · BioWorld12:00 PMLilly’s delivery tech search continues with $1B Metis deal — BioWorld
- 12:00 PM · BioWorld12:00 PMJapan's expanded drug price cuts draw industry backlash — BioWorld
- 12:00 PM · BioWorld12:00 PMGSK’s Jemperli wins accelerated nod in rectal cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMAbbott secures CE mark certification for Cologuard Plus — BioWorld
- 11:55 AM · BioPharma Dive11:55 AMMost new drugs are still too costly at launch, ICER says — BioPharma Dive
- 11:06 AM · Drug Discovery World11:06 AMCarterra advances lab-in-the-loop drug discovery — Drug Discovery World